medigraphic.com
SPANISH

Salud Mental

ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2009, Number 5

<< Back Next >>

Salud Mental 2009; 32 (5)

Psychiatric complications of a late diagnosis of acute porphyria in an affected male

Elizondo CG, Hernández AMD, Rangel GR, Arteaga AMG
Full text How to cite this article

Language: English
References: 18
Page: 365-369
PDF size: 90.51 Kb.


Key words:

Psychosis, porphyria, heme, coproporphyria.

ABSTRACT

Introduction: Acute porphyrias are rare genetic disorders of incomplete penetrance (10%). This means that only 10% of the individuals with the genotype known to cause the disease will show any signs or symptoms of such disease. They consist of a deficiency of any enzyme of the heme biosynthesis and are considered as exceptional inborn errors of metabolism with an autosomal dominant inheritance. The incidence is 1 in 100 000. The symptoms are variable and unspecific, consisting mainly of severe abdominal pain, tachycardia, and hypertension. Other frequent manifestations are psychiatric symptoms like depression, psychosis, and hallucinations. In addition to these unspecific symptoms, patients may also present peripheral neuropathy and loss of sensation, which can become permanent. In severe cases, liver damage and chronic renal disease can occur. The objective of this study is to highlight the importance of the difficult diagnosis of acute porphyria, the implications of a misdiagnosis, and the importance of adequate treatment.
Case: We present a 47 year-old male with a history of abdominal pain for seven years. The pain was diffuse, progressive, and incapacitating. He was diagnosed and treated for chronic gastritis and cholecystitis without improvement. An elective cholecystectomy was performed but he continued with intense abdominal pain. Three years later he developed hallucinations, paresthesias, muscular weakness, depression, and irritability. He was managed as a psychiatric patient with psychotic tendencies. After a complete and thorough history of all his symptoms throughout the years and a re-examination of the patient, acute porphyria was considered as a possible diagnosis. Specific laboratory studies were indicated revealing elevated levels of porphyrines, elevated levels of PBGD, PBG in urine within normal levels, elevated presence of coproporphyrines by chromatography, and a normal PBGD enzymatic activity. The diagnosis of acute porphyria was established. Appropriate treatment was initiated starting with adequate pain management. A high carbohydrate diet was also recommended with appropriate nutritional requirements and caloric intake. Another important aspect of the management was the elimination of risk factors, like alcohol, cigarette smoking, and certain specific medications. Follow-up showed significant improvement of his symptoms and less frequent acute attacks with identification and elimination of risk factors. He was able to return to a stable work schedule. The patient presents residual permanent renal damage. Adequate doctor-patient education was maintained.
Discussion: This case is an important example of a not-so-rare genetic disease that any physician should have in mind when confronted with a patient with unspecific paroxysmal clinical manifestations. The possibility of acute porphyria should always be excluded before establishing a diagnosis of a psychiatric illness. Prompt diagnosis and management are crucial to reduce the risk of recurrences and permanent damage. Patient education is a very important aspect of the management of the disease since there is no cure. There is a specific treatment for the management of acute attacks (Hemin) but, unfortunately, it is still unavailable in our country. This is a problem that turns the management and prevention of risk factors into the most important tools we have to improve our patients’ quality of life.


REFERENCES

  1. Anderson KE. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142:439-450.

  2. Andersson C, Innala E, Backstrom T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. J Intern Med 2003;254:176-183.

  3. Scriver CR. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. Metabolic molecular bases of inherited disease. McGraw-Hill; 2001.

  4. Rimoin DL. Inherited porphyrias. Emery and rimoin’s principles and practice of medical genetics. Elsavier; 2007.

  5. Schuurmans MM, Xianoye Schneider-Yin, Schyder C, Minder C et al. Influence of age and gender on the clinical expression of acute intermittent porphyria Based on molecular study of porphobilinogen deaminase gene among Swiss patients. Mol Med 2001;7(8):535-542.

  6. Gross U, Puy H, Meissauer U, Lamoril J, Deybach JC et al. A molecular, enzymatic and clinical study in a family with hereditary coproporphyria. J Inherit Metab Dis 2002;25:279-286.

  7. Cacheux V, Martasek P, Fougerousse F, Delfau MH, Druart L et al. Localization of the human coproporphyrinogen oxidase gene to chromosome band 3q12. Hum Genet 1994;94:557-559.

  8. González-Arriaza HL, Bostwick JM. Acute porphyrias: A case report and review. Am J Psychiatry 2003;160:450-459.

  9. Brennan MJ, Cantrill RC. Delta-aminolaevulinic acid and amino acid neurotransmitters. Mol Cell Biochem 1981;(spec no):49-58.

  10. Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med 1996; 240: 195-201.

  11. Kauppinen R, Von Und Zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their amilies. Clin Chem 2002;48(11):1891-1900.

  12. Andersson C, Wikberg A, Stegmayr B, Lithner F. Renal symptomatology in patients with acute intermittent porphyria. A population-based study. J Intern Med 2000;248:319-325.

  13. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 1993;153:2004-2008.

  14. Jeans JB, Savik K, Gross CR, Weimer MK, Bossenmaier IC et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet 1996;65:269-273.

  15. Deacon AC, Peters TJ. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem 1998;6:726-732.

  16. Bonkowsky HL, Tschudy DP, Doherty J, Bossenmaier I, Cardinal R et al. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intraveonous infusions of hematin. Proc Natl Acad Sci U S A 1971;68(11):2725-2729.

  17. Castellanos G, Anguiano G. Aspectos bioquímicos de la porfiria aguda intermitente. Neurología-Neurocirugía-Psiquiatría 1967;8(3):145-168.

  18. Sardana MK, Padmanaban G. Effect of 2-Allyl-2-isopropylacetamide on poly(adenylic acid)-contailing Ribonucleic Acid. Biochem J 1976;158:169-174.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Salud Mental. 2009;32